2cureX
2.21 SEK
-16.60 %
Less than 1K followers
2CUREX
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
-16.60 %
+190.79 %
+329.96 %
+105.58 %
-11.60 %
+402.27 %
-72.24 %
-88.02 %
-70.95 %
2cureX is a Danish-based biotech company with subsidiary in Hamburg, Germany. The company has made a special sensitivity test, IndiTreat, for oncology clinics that is focused on improving the outcome for cancer patients by improving the efficiency of the individual cancer treatment. IndiTreat uses a biopsy from the individual cancer patient to measure and predict the likely outcome of different available treatments, thereby assisting oncologists to choose the most effective treatment for the individual patient.
Read moreMarket cap
55.48M SEK
Turnover
1.92M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26/2
2026
Annual report '25
25/6
2026
General meeting '26
27/8
2026
Interim report Q2'26
All
Press releases
3rd party
ShowingAll content types
2cureX AB (“2cureX”) hereby publishes the interim report for the first half year of 2025.
Improved communication from 2cureX AB
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools